Differential Hepatitis B Surface Antigen Glycan Isomer Kinetics Between Tenofovir Alafenamide and Entecavir: Hepatocellular Carcinoma Risk Stratification in Hepatitis B e Antigen‐Positive Patients
Journal of Viral Hepatitis · 2026
DOI: 10.1111/jvh.70218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von Yuji Kita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Guanine, Liver Neoplasms, Antiviral Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: JIMRO, Otsuka Pharmaceutical, Taiho Pharma.
Abstract (Originalsprache)
Nucleos(t)ide analog (NA) therapy suppresses hepatitis B virus (HBV) DNA, but residual hepatocellular carcinoma (HCC) risk persists. O‐glycosylated hepatitis B surface antigen glycan isomer (HBsAgGi) uniquely reflects virion burden. We evaluated the impact of tenofovir alafenamide (TAF) versus entecavir (ETV) on 48‐week HBsAgGi kinetics and its utility in stratifying HCC risk in 90 NA‐naïve patients (ETV: 73; TAF: 17). A favourable response was defined as a reduction or maintenance of low HBsAgGi levels. TAF independently predicted a favourable response compared with ETV (penalised odds ratio 3.60, p = 0.030). A significant interaction occurred between HBeAg status and HBsAgGi response in relation to HCC development ( p = 0.038). In HBeAg‐positive patients, a poor response was associated with increased HCC risk (hazard ratio 7.34, 95% confidence interval [CI] 1.96–20.35, p = 0.001); however, the exact magnitude warrants cautious interpretation due to wide CIs. This association was absent in HBeAg‐negative cases. Adding HBsAgGi response to the aMAP score improved long‐term HCC prediction exclusively in the HBeAg‐positive cohort. As the assay targets genotype C‐specific O‐glycosylation, the findings cannot be generalised to genotypes A, B, or D. In conclusion, on‐treatment HBsAgGi response is a specific surrogate marker for stratifying residual HCC risk in HBeAg‐positive patients, and TAF is more effective than ETV in inducing these favourable kinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
ORCID-Profile: Shunsuke Sato, Yuji Shimada, Takuya Genda
Förderung
- JIMRO
- Otsuka Pharmaceutical
- Taiho Pharma
- Taiho Pharmaceutical
Zitieren
APA
Kita, Y., Murata, A., Nago, H., Yamaguchi, M., Kato, Y., Om, R., Terai, Y., Ikeda, Y., Sato, S., Sato, S., Shimada, Y., & Genda, T. (2026). Differential Hepatitis B Surface Antigen Glycan Isomer Kinetics Between Tenofovir Alafenamide and Entecavir: Hepatocellular Carcinoma Risk Stratification in Hepatitis B e Antigen‐Positive Patients. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70218
Vancouver
Kita Y, Murata A, Nago H, Yamaguchi M, Kato Y, Om R, et al. Differential Hepatitis B Surface Antigen Glycan Isomer Kinetics Between Tenofovir Alafenamide and Entecavir: Hepatocellular Carcinoma Risk Stratification in Hepatitis B e Antigen‐Positive Patients. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70218
BibTeX
@article{Kita2026,
author = {Kita, Yuji and Murata, Ayato and Nago, Hiroki and Yamaguchi, Masahiro and Kato, Yoko and Om, Rihwa and Terai, Yuichro and Ikeda, Yuji and Sato, Sho and Sato, Shunsuke and Shimada, Yuji and Genda, Takuya},
title = {Differential Hepatitis B Surface Antigen Glycan Isomer Kinetics Between Tenofovir Alafenamide and Entecavir: Hepatocellular Carcinoma Risk Stratification in Hepatitis B e Antigen‐Positive Patients},
journal = {Journal of Viral Hepatitis},
year = {2026},
doi = {10.1111/jvh.70218}
}
EUVIMED